Pub. Date : 2017 Sep 26
PMID : 29088743
10 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | In vitro and in vivo anti-tumor activity of alectinib in tumor cells with NCOA4-RET. | alectinib | ret proto-oncogene | Homo sapiens |
| 2 | Alectinib, an approved ALK inhibitor, is reported to inhibit KIF5B-RET and CCDC6-RET. | alectinib | ret proto-oncogene | Homo sapiens |
| 3 | Alectinib, an approved ALK inhibitor, is reported to inhibit KIF5B-RET and CCDC6-RET. | alectinib | ret proto-oncogene | Homo sapiens |
| 4 | However, the activity of alectinib with respect to RET with other fusion partners is unknown. | alectinib | ret proto-oncogene | Homo sapiens |
| 5 | In the present study, we investigated the effects of alectinib on NCOA4-RET fusion-positive tumor cells in vitro and in vivo. | alectinib | ret proto-oncogene | Homo sapiens |
| 6 | Alectinib inhibited the viability of NCOA4-RET-positive EHMES-10 cells, as well as CCDC6-RET-positive LC-2/ad and TPC-1 cells. | alectinib | ret proto-oncogene | Homo sapiens |
| 7 | These results suggest that alectinib may be a promising RET inhibitor against tumors positive for not only KIF5B-RET and CCDC6-RET, but also NCOA4-RET. | alectinib | ret proto-oncogene | Homo sapiens |
| 8 | These results suggest that alectinib may be a promising RET inhibitor against tumors positive for not only KIF5B-RET and CCDC6-RET, but also NCOA4-RET. | alectinib | ret proto-oncogene | Homo sapiens |
| 9 | These results suggest that alectinib may be a promising RET inhibitor against tumors positive for not only KIF5B-RET and CCDC6-RET, but also NCOA4-RET. | alectinib | ret proto-oncogene | Homo sapiens |
| 10 | These results suggest that alectinib may be a promising RET inhibitor against tumors positive for not only KIF5B-RET and CCDC6-RET, but also NCOA4-RET. | alectinib | ret proto-oncogene | Homo sapiens |